FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2038163957> ?p ?o ?g. }

• W2038163957 endingPage "556" @default.
• W2038163957 startingPage "547" @default.
• W2038163957 abstract "Purpose:Trastuzumab induced cardiotoxicity (TIC) was defined as the most serious side effect. Long term cardiac effects of trastuzumab are still not known, thus we aimed to compare the long term cardiac effects of adjuvant trastuzumab therapies of HER2-positive breast cancer according to the treatment duration.Methods:Patients who completed adjuvant trastuzumab treatment at least 6 months before for the adjuvant setting in HER2-positive breast cancer were included in the study. A total of 164 patients were included in this study: 108 and 56 patients were treated with 9 weeks and 52 weeks of trastuzumab, respectively. The main limitation of our study is that due to the cross-sectional evaluation of cardiac biomarkers we cannot predict the status of baseline cardiac biomarkers of this population.Results:The median follow-up of the study was 32 (10–95) months. The accompanying chronic diseases were similar in both groups. Baseline left ventricular ejection fraction (LVEF) was 65.5 ± 3.4% vs 67.1 ± 4.5% in the 9 weeks and 52 weeks trastuzumab treatment groups, respectively (p = 0.13). Symptomatic heart failure was not observed during trastuzumab treatment in either group. Trastuzumab induced cardiotoxicity (TIC) was observed in 2 (1.9%) and 17 (30.3%) patients in the 9 and 52 weeks trastuzumab treatment groups, respectively (p < 0.001). After a median 24 months of follow-up from the last dose of trastuzumab, mean LVEF values were similar between the two treatment arms (p = 0.29). In the subgroup analyses, mean LVEF values were significantly lower in patients who developed TIC compared to those who did not develop TIC (61.9 ± 3.6% vs 64.4 ± 2.6%, p = 0.04). Average mean LVEF loss from baseline was significantly higher in patients who developed TIC compared to those who did not develop TIC (10.0 ± 6.0% vs 1.5 ± 6.2%, p < 0.001). Cardiac biomarkers were similar in both treatment groups. In the subgroup analyses serum High-sensitivity C-reactive protein (hs-CRP) and prohormone brain natriuretic peptide (pro-BNP) levels were significantly higher in patients who developed TIC compared to those who did not develop TIC.Conclusions:TIC was observed to be significantly higher in the 52 weeks trastuzumab group. At the end of 32 months of follow-up mean LVEF values and cardiac biomarkers were similar between the two treatment groups. In the subgroup analyses, significant LVEF loss and higher cardiac biomarkers which show cardiac damage in patients who developed TIC can be permanent in some of the patients and long term cardiac damage may be underestimated." @default.
• W2038163957 created "2016-06-24" @default.
• W2038163957 creator A5002199508 @default.
• W2038163957 creator A5006363327 @default.
• W2038163957 creator A5029262292 @default.
• W2038163957 creator A5052112651 @default.
• W2038163957 creator A5052748672 @default.
• W2038163957 creator A5054275694 @default.
• W2038163957 creator A5055548954 @default.
• W2038163957 creator A5074974662 @default.
• W2038163957 creator A5089097501 @default.
• W2038163957 creator A5090532877 @default.
• W2038163957 date "2015-01-27" @default.
• W2038163957 modified "2023-10-14" @default.
• W2038163957 title "Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer" @default.
• W2038163957 cites W1970029906 @default.
• W2038163957 cites W1980322984 @default.
• W2038163957 cites W1982210988 @default.
• W2038163957 cites W2012894160 @default.
• W2038163957 cites W2013429820 @default.
• W2038163957 cites W2037013151 @default.
• W2038163957 cites W2050674912 @default.
• W2038163957 cites W2061764831 @default.
• W2038163957 cites W2083486298 @default.
• W2038163957 cites W2084960434 @default.
• W2038163957 cites W2093332042 @default.
• W2038163957 cites W2096818458 @default.
• W2038163957 cites W2096884232 @default.
• W2038163957 cites W2098775844 @default.
• W2038163957 cites W2099067294 @default.
• W2038163957 cites W2101253730 @default.
• W2038163957 cites W2107427447 @default.
• W2038163957 cites W2108513123 @default.
• W2038163957 cites W2109775164 @default.
• W2038163957 cites W2122472092 @default.
• W2038163957 cites W2125620887 @default.
• W2038163957 cites W2129816567 @default.
• W2038163957 cites W2133201432 @default.
• W2038163957 cites W2136166698 @default.
• W2038163957 cites W2137159389 @default.
• W2038163957 cites W2137983259 @default.
• W2038163957 cites W2140074016 @default.
• W2038163957 cites W2140354367 @default.
• W2038163957 cites W2143967622 @default.
• W2038163957 cites W2144124503 @default.
• W2038163957 cites W2144848856 @default.
• W2038163957 cites W2146384083 @default.
• W2038163957 cites W2148238586 @default.
• W2038163957 cites W2149795152 @default.
• W2038163957 cites W2149908785 @default.
• W2038163957 cites W2151353276 @default.
• W2038163957 cites W2152647863 @default.
• W2038163957 cites W2154066911 @default.
• W2038163957 cites W2160329331 @default.
• W2038163957 cites W2169281409 @default.
• W2038163957 cites W2318605753 @default.
• W2038163957 cites W3022179669 @default.
• W2038163957 cites W4239462698 @default.
• W2038163957 doi "https://doi.org/10.1185/03007995.2015.1005834" @default.
• W2038163957 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25586297" @default.
• W2038163957 hasPublicationYear "2015" @default.
• W2038163957 type Work @default.
• W2038163957 sameAs 2038163957 @default.
• W2038163957 citedByCount "9" @default.
• W2038163957 countsByYear W20381639572016 @default.
• W2038163957 countsByYear W20381639572017 @default.
• W2038163957 countsByYear W20381639572021 @default.
• W2038163957 countsByYear W20381639572022 @default.
• W2038163957 crossrefType "journal-article" @default.
• W2038163957 hasAuthorship W2038163957A5002199508 @default.
• W2038163957 hasAuthorship W2038163957A5006363327 @default.
• W2038163957 hasAuthorship W2038163957A5029262292 @default.
• W2038163957 hasAuthorship W2038163957A5052112651 @default.
• W2038163957 hasAuthorship W2038163957A5052748672 @default.
• W2038163957 hasAuthorship W2038163957A5054275694 @default.
• W2038163957 hasAuthorship W2038163957A5055548954 @default.
• W2038163957 hasAuthorship W2038163957A5074974662 @default.
• W2038163957 hasAuthorship W2038163957A5089097501 @default.
• W2038163957 hasAuthorship W2038163957A5090532877 @default.
• W2038163957 hasConcept C121608353 @default.
• W2038163957 hasConcept C126322002 @default.
• W2038163957 hasConcept C143998085 @default.
• W2038163957 hasConcept C164705383 @default.
• W2038163957 hasConcept C2776694085 @default.
• W2038163957 hasConcept C2777863537 @default.
• W2038163957 hasConcept C2778198053 @default.
• W2038163957 hasConcept C2778233292 @default.
• W2038163957 hasConcept C2779786085 @default.
• W2038163957 hasConcept C2908647359 @default.
• W2038163957 hasConcept C530470458 @default.
• W2038163957 hasConcept C71924100 @default.
• W2038163957 hasConcept C78085059 @default.
• W2038163957 hasConcept C99454951 @default.
• W2038163957 hasConceptScore W2038163957C121608353 @default.
• W2038163957 hasConceptScore W2038163957C126322002 @default.
• W2038163957 hasConceptScore W2038163957C143998085 @default.
• W2038163957 hasConceptScore W2038163957C164705383 @default.
• W2038163957 hasConceptScore W2038163957C2776694085 @default.

• next